CY1120018T1 - Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα - Google Patents

Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Info

Publication number
CY1120018T1
CY1120018T1 CY20181100301T CY181100301T CY1120018T1 CY 1120018 T1 CY1120018 T1 CY 1120018T1 CY 20181100301 T CY20181100301 T CY 20181100301T CY 181100301 T CY181100301 T CY 181100301T CY 1120018 T1 CY1120018 T1 CY 1120018T1
Authority
CY
Cyprus
Prior art keywords
antibodies
receptor
compounds
rheumatoid arthritis
binding
Prior art date
Application number
CY20181100301T
Other languages
English (en)
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1120018T1 publication Critical patent/CY1120018T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

Η παρούσα περιγραφή αναφέρεται σε μια καινοτόμο χρήση ενώσεων που διακόπτουν την σύνδεση IL1β συνδέτη/ IL-1 υποδοχέα (στο παρόν αναφερόμενες ως «IL-1 βήτα ενώσεις»), όπως είναι μικρομοριακές ενώσεις που διακόπτουν την αλληλεπίδραση του IL-1β συνδέτη- IL-1 υποδοχέα, IL-1β αντισώματα ή αντισώματα έναντι του IL-1 υποδοχέα, π.χ. μόρια που συνδέονται με την IL-1β που περιγράφονται στο παρόν, π.χ. αντισώματα τα οποία περιγράφονται στο παρόν, π.χ. ενώσεις που συνδέονται με την IL-1β ή ενώσεις που συνδέονται με τον υποδοχέα της IL-1, και/ή ενώσεις RNA που ελαττώνουν είτε τα επίπεδα των συνδετών IL-1β ή τα επίπεδα των πρωτεϊνικών υποδοχέων της IL-1, την θεραπεία και/ή στην πρόληψη αυτό-φλεγμονωδών συνδρόμων, π.χ. του συνδρόμου της νεανικής ρευματοειδούς αρθρίτιδας ή της ρευματοειδούς αρθρίτιδας των ενηλίκων και σε μεθόδους θεραπείας και/ή πρόληψης αυτό- φλεγμονωδών συνδρόμων, π.χ. του συνδρόμου της του συνδρόμου της νεανικής ρευματοειδούς αρθρίτιδας ή της ρευματοειδούς αρθρίτιδας των ενηλίκων, στα θηλαστικά και συγκεκριμένα στον άνθρωπο.
CY20181100301T 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα CY1120018T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies
EP10181100A EP2332577A1 (en) 2005-10-26 2006-10-24 Novel use of IL-1beta compounds

Publications (1)

Publication Number Publication Date
CY1120018T1 true CY1120018T1 (el) 2018-12-12

Family

ID=37806690

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I1 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I1 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Country Status (29)

Country Link
US (8) US8105587B2 (el)
EP (5) EP4218815A3 (el)
JP (4) JP2009513645A (el)
KR (3) KR101749388B1 (el)
CN (2) CN102861332A (el)
AU (1) AU2006306280B2 (el)
BR (1) BRPI0617830B8 (el)
CA (3) CA2898369C (el)
CY (4) CY1113378T1 (el)
DK (2) DK2848258T3 (el)
ES (3) ES2389110T3 (el)
HK (3) HK1121041A1 (el)
HU (2) HUE036973T2 (el)
IL (4) IL190545A (el)
JO (2) JO2826B1 (el)
LT (3) LT2848258T (el)
LU (2) LU92326I2 (el)
MA (1) MA29919B1 (el)
NO (2) NO345888B1 (el)
NZ (1) NZ567222A (el)
PH (2) PH12013501287B1 (el)
PL (2) PL1940465T3 (el)
PT (2) PT1940465E (el)
RU (2) RU2468817C2 (el)
SI (2) SI1940465T1 (el)
TN (1) TNSN08189A1 (el)
TR (1) TR201802449T4 (el)
TW (3) TWI388335B (el)
WO (1) WO2007050607A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861332A (zh) 2005-10-26 2013-01-09 诺瓦提斯公司 IL-1β化合物的新用途
US8282922B2 (en) * 2007-05-29 2012-10-09 Novartis Ag Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
AU2012203931B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
PT2293816E (pt) * 2008-06-06 2013-02-13 Xoma Technology Ltd Métodos para o tratamento da artrite reumatoide
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
BR112012007365A2 (pt) * 2009-10-15 2016-11-22 Abbott Lab proteínas de ligação à il-1
AR081246A1 (es) * 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
US8853365B2 (en) * 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
MX362132B (es) 2011-05-10 2019-01-07 Nestec Sa Metodos para perfilado de actividad de enfermedad para manejo de terapia personalizado.
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
CA3135012A1 (en) 2017-05-31 2018-12-06 Anjali Jain Methods for assessing mucosal healing in crohn's disease patients
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
JP2021523894A (ja) 2018-05-09 2021-09-09 ノバルティス アーゲー カナキヌマブの使用
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
EP3897613A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
KR20230109107A (ko) * 2022-01-10 2023-07-19 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH08508415A (ja) 1993-12-14 1996-09-10 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 結合組織疾患の全身的遺伝子治療
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
JP2003500005A (ja) 1999-02-10 2003-01-07 インターリューキン ジェネティックス インコーポレイテッド ＩＬ−１β遺伝子の突然変異に基づく治療および診断
KR20020022778A (ko) * 1999-07-16 2002-03-27 룬딩 에른스트 ＩＬ-1β 및 ＴＮＦ-α억제제로서의 아미노벤조페논
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2241328A1 (en) 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP4234426B2 (ja) 2000-11-07 2009-03-04 ノバルティス アクチエンゲゼルシャフト プロテインキナーゼｃインヒビターとしてのインドリルマレイミド誘導体
AU2002355249A1 (en) * 2001-07-26 2003-02-17 Eli Lilly And Company Interleukin-1 beta antibodies
EP1450837A4 (en) 2001-08-07 2006-01-04 Immunex Corp INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
AU2002365713A1 (en) 2001-12-01 2003-06-17 John Charles Balson Ac synchronous generator incorporating a braking mechansim
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
CA2474360A1 (en) 2002-02-11 2003-08-21 Arkion Life Sciences Llc Purified cytokine inhibitory factor
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
US7365096B2 (en) 2002-12-09 2008-04-29 Board Of Regents, The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
EP1590369B1 (en) * 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
AU2005249503B2 (en) 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
JP2007510931A (ja) 2003-11-10 2007-04-26 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｉｌ−１８をモニターするための方法
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
CN1964737B (zh) * 2004-06-04 2011-04-20 瑞泽恩制药公司 利用il-1拮抗剂治疗自身炎症性疾病的方法
US8003779B2 (en) 2005-01-20 2011-08-23 University Of Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
EA016258B1 (ru) 2005-03-18 2012-03-30 Микробиа, Инк. Рекомбинантные грибы, продуцирующие каротиноиды, и способы их применения
ATE446972T1 (de) 2005-06-21 2009-11-15 Xoma Technology Ltd Il-1 bindende antikörper und fragmente davon
CN102861332A (zh) * 2005-10-26 2013-01-09 诺瓦提斯公司 IL-1β化合物的新用途

Also Published As

Publication number Publication date
AU2006306280A1 (en) 2007-05-03
EP3332807A3 (en) 2018-06-20
CA2898369C (en) 2017-06-20
IL258983A (en) 2018-06-28
AU2006306280B2 (en) 2010-06-17
CA2898369A1 (en) 2007-05-03
CN102861332A (zh) 2013-01-09
BRPI0617830B8 (pt) 2021-05-25
JP2016020377A (ja) 2016-02-04
EP4218815A2 (en) 2023-08-02
KR20080059598A (ko) 2008-06-30
ES2944067T3 (es) 2023-06-19
US20130171167A1 (en) 2013-07-04
EP2848258B1 (en) 2017-12-13
RU2008120625A (ru) 2010-01-20
US20120039910A1 (en) 2012-02-16
TWI626056B (zh) 2018-06-11
WO2007050607A2 (en) 2007-05-03
JP2013166757A (ja) 2013-08-29
RU2468817C2 (ru) 2012-12-10
IL245387A0 (en) 2016-06-30
TW200803898A (en) 2008-01-16
PL1940465T3 (pl) 2013-01-31
IL190545A (en) 2016-09-29
WO2007050607A3 (en) 2007-06-28
CY1113378T1 (el) 2015-11-04
TWI388335B (zh) 2013-03-11
RU2012133522A (ru) 2014-02-20
TW201302220A (zh) 2013-01-16
PT1940465E (pt) 2012-10-03
EP2332577A1 (en) 2011-06-15
PH12020500559A1 (en) 2021-06-14
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
ES2389110T3 (es) 2012-10-23
EP1940465B1 (en) 2012-08-01
NO20082344L (no) 2008-07-22
US8105587B2 (en) 2012-01-31
JP2017206552A (ja) 2017-11-24
PT2848258T (pt) 2018-03-20
CY2013046I2 (el) 2015-11-04
LTC1940465I2 (lt) 2017-12-11
LU92326I2 (fr) 2014-02-05
PH12013501287A1 (en) 2016-02-01
US20080286266A1 (en) 2008-11-20
RU2571563C2 (ru) 2015-12-20
HUE036973T2 (hu) 2018-08-28
DK2848258T3 (en) 2018-03-19
ES2662420T3 (es) 2018-04-06
DK1940465T3 (da) 2012-10-22
PH12013501287B1 (en) 2016-02-01
CA2626214A1 (en) 2007-05-03
CY2013046I1 (el) 2015-11-04
BRPI0617830A2 (pt) 2011-08-09
KR20150013834A (ko) 2015-02-05
NO345888B1 (no) 2021-09-27
JOP20140120B1 (ar) 2021-08-17
IL190545A0 (en) 2008-11-03
EP3332807A2 (en) 2018-06-13
JP2009513645A (ja) 2009-04-02
HK1204767A1 (en) 2015-12-04
CA2626214C (en) 2016-06-21
KR101518064B1 (ko) 2015-05-06
SI2848258T1 (en) 2018-03-30
JP6061747B2 (ja) 2017-01-18
LTC2848258I2 (lt) 2019-08-12
CY2018018I1 (el) 2018-12-12
HK1121041A1 (en) 2009-04-17
EP3332807B1 (en) 2023-02-22
TNSN08189A1 (en) 2009-10-30
HUS1800025I1 (hu) 2018-07-30
EP1940465A2 (en) 2008-07-09
US20210147533A1 (en) 2021-05-20
IL245387B (en) 2019-09-26
IL258983B (en) 2020-10-29
JP6286403B2 (ja) 2018-02-28
EP4218815A3 (en) 2024-03-27
KR101749388B1 (ko) 2017-06-20
IL277406A (en) 2020-11-30
LU92326I9 (el) 2019-01-16
CN101291693B (zh) 2012-10-03
US20170218063A1 (en) 2017-08-03
NO20200810A1 (no) 2008-07-22
PL2848258T3 (pl) 2018-06-29
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
MA29919B1 (fr) 2008-11-03
EP2848258A1 (en) 2015-03-18
LTPA2018506I1 (lt) 2018-06-25
TW201617097A (zh) 2016-05-16
SI1940465T1 (sl) 2012-10-30
HK1252316A1 (zh) 2019-05-24
JO2826B1 (en) 2014-09-15
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
US8409576B2 (en) 2013-04-02
CN101291693A (zh) 2008-10-22
US20150322148A1 (en) 2015-11-12
US20180201674A1 (en) 2018-07-19
BRPI0617830B1 (pt) 2020-10-20
TR201802449T4 (tr) 2018-03-21
LT2848258T (lt) 2018-02-26
CY2018018I2 (el) 2018-12-12
TWI537003B (zh) 2016-06-11
CA2963828A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
CY1120018T1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
CY1123609T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1111065T1 (el) Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1122605T1 (el) Θεραπεια δεοξυνουκλεοσιδιου για νοσους οι οποιες οφειλονται σε μη ισορροπημενες ομαδες νουκλεοτιδιων, οπου συμπεριλαμβανονται συνδρομα εξαντλησης μιτοχονδριακου dna
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
MX2009012948A (es) Nuevas indicaciones para la terapia anti-il-1-beta.
CY1120135T1 (el) Αναστολεις κινασης τυροσινης bruton
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1116288T1 (el) Tnfsf απλης αλυσου μορια
CY1106070T1 (el) Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
BRPI0519044B8 (pt) anticorpo monoclonal direcionado contra o antígeno cd20 e seu uso
ATE526987T1 (de) Dr5-antikörper und deren verwendung
NO20072733L (no) Doseformer
CU23719A3 (es) Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
CY1113404T1 (el) Μεθοδος αντιμετωπισης ή προληψης της πολυ- οργανικης ανεπαρκειας